Magnesium‑UDP‑GlcNAc nanosheet (MgUGN) activates lysosomal AMPK and reduces hepatic steatosis and inflammation in mouse models

The Numbers

This study on the magnesium-coordinated UDP-GlcNAc nanosheet (MgUGN) primarily utilized mouse models, and while the abstract reports qualitative improvements, it does not provide specific quantified results such as percentages of reduction in hepatic steatosis, inflammation markers, or p-values for statistical significance. The exact sample size for the animal cohorts was not explicitly stated. Nonetheless, the findings indicate:

• Elevated basal AMP-activated protein kinase (AMPK) activity in mouse liver and muscle following ROAM1 silencing.


• Induction of a transcriptional state inhibiting lipid synthesis in these tissues.


• Improved lipid metabolism and reduced hepatic steatosis in mouse models of metabolic disease after MgUGN treatment.


• Mitigation of liver damage and decreased inflammation in acute liver injury mouse models following MgUGN treatment.

Context: What This Study Is

Authored by Zhu et al. from the Shenzhen Key Laboratory of Bone Tissue Repair and Translational Research, this research investigated novel pathways and therapeutic strategies for Metabolic dysfunction-associated steatotic liver disease (MASLD). Current AMPK activators for MASLD often demonstrate unsatisfactory clinical efficacy, possibly due to complex activation mechanisms and abundant substrates. This study aimed to identify and target lysosome-specific AMPK activation as a precision therapy.

The researchers employed a bimolecular fluorescence complementation (BiFC)-based protein interaction screen to identify ROAM1 (renamed from SLC35F6), a nucleotide-sugar transporter, as an AMPKβ-interacting protein localized to the lysosome. Following this discovery, they conducted *in vivo* studies involving silencing ROAM1 in mouse liver and muscle. To evaluate therapeutic potential, an engineered magnesium-coordinated UDP-GlcNAc nanosheet (MgUGN) was developed for efficient *in vivo* delivery, and subsequently administered to mouse models of metabolic disease and acute liver injury.

What This Result Means

This study significantly advances our understanding of AMPK regulation, particularly within the lysosome, a cellular compartment increasingly recognized for its role in metabolism. The identification of ROAM1 as a novel AMPKβ-interacting protein that negatively regulates AMPK activity introduces a previously uncharacterized control point for this master metabolic enzyme. UDP-GlcNAc, identified as the ligand for ROAM1, activates lysosomal AMPK through the ROAM1-AMPKβ axis, specifically influencing lipid metabolism. This mechanism explains how specific nutrient signals, like UDP-GlcNAc, can finely tune AMPK activity at a subcellular level to regulate lipid synthesis.

The development and testing of MgUGN represent a critical step toward compartment-specific activation of AMPK. By directly targeting the UDP-GlcNAc-ROAM1-AMPK axis with an engineered nanosheet, the researchers demonstrated a functional therapeutic approach. The observed improvements in lipid metabolism, reductions in hepatic steatosis, and decreased inflammation in mouse models suggest a potent strategy for addressing the core pathologies of MASLD and liver injury, potentially bypassing the limitations of broader, systemic AMPK activation.

Study Limitations

• The research was conducted exclusively in mouse models, which, despite offering valuable mechanistic insights, may not fully translate to human physiology or the complex etiology of MASLD in humans.


• The abstract does not report specific quantitative results (e.g., percentages, p-values, or effect sizes) for the observed improvements in hepatic steatosis, lipid metabolism, or inflammation following MgUGN treatment, limiting the precise understanding of the magnitude of effect.


• The sample size for the animal cohorts utilized in the MgUGN treatment arms was not explicitly stated within the abstract, which can affect the generalizability and statistical power of the findings.

Practical Application

This study identifies the UDP-GlcNAc-ROAM1-AMPK axis as a novel regulator of hepatic lipid metabolism and introduces MgUGN as a potential compartment-specific AMPK activator. It is too early to apply these findings to a personal protocol for human performance optimization or longevity. Before this pathway or MgUGN could be considered actionable for human use, extensive further research would be required, including validation in human cells, replication in larger animal cohorts, and ultimately, rigorously designed human clinical trials to establish efficacy, safety, optimal dosing, and delivery methods.

Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.